McKesson (NYSE:MCK) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded McKesson to a "buy", and overall 14 analysts rate the stock Buy vs. 3 Hold, giving a consensus "Moderate Buy" with an average price target of $972.27.
• McKesson beat Q4 estimates, reporting EPS of $9.34 vs. $9.19 and revenue of $106.16 billion (up 11.4% YoY), and issued FY2026 EPS guidance of $38.80–$39.20 (sell‑side forecast ~39.02).
• The shares opened at $814.69 (52‑week range $637–$999) with a market cap of about $99.8B and a P/E of 23.4; meanwhile insiders sold roughly 3,592 shares (~$3.52M) in the last 90 days and institutional investors own about 85.07% of the stock.

McKesson (NYSE:MCK - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

Several other research firms also recently issued reports on MCK. Bank of America cut their price target on McKesson from $1,040.00 to $1,000.00 and set a "buy" rating for the company in a research note on Monday, April 6th. UBS Group cut their price target on McKesson from $1,012.00 to $1,000.00 and set a "buy" rating for the company in a research note on Wednesday, April 22nd. Robert W. Baird set a $968.00 price target on McKesson in a research note on Wednesday, January 14th. TD Cowen lifted their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a "buy" rating in a research note on Thursday, February 5th. Finally, Raymond James Financial set a $970.00 price target on McKesson in a research note on Thursday, March 5th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, McKesson presently has a consensus rating of "Moderate Buy" and an average target price of $972.27.

McKesson Stock Performance

McKesson stock opened at $814.69 on Friday. McKesson has a one year low of $637.00 and a one year high of $999.00. The business has a fifty day moving average of $894.86 and a two-hundred day moving average of $859.16. The company has a market cap of $99.79 billion, a P/E ratio of 23.43, a price-to-earnings-growth ratio of 1.18 and a beta of 0.35.

McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts' consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter last year, the company earned $8.03 earnings per share. McKesson's quarterly revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts predict that McKesson will post 39.02 EPS for the current year.

Insider Buying and Selling

In related news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares in the company, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president owned 2,989 shares of the company's stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is owned by company insiders.

Institutional Trading of McKesson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in McKesson by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,104,719 shares of the company's stock worth $9,929,380,000 after purchasing an additional 73,109 shares in the last quarter. State Street Corp increased its position in McKesson by 0.5% during the 4th quarter. State Street Corp now owns 5,780,179 shares of the company's stock worth $4,746,118,000 after purchasing an additional 29,660 shares in the last quarter. Geode Capital Management LLC increased its position in McKesson by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 2,857,344 shares of the company's stock worth $2,333,520,000 after purchasing an additional 25,082 shares in the last quarter. Franklin Resources Inc. increased its position in McKesson by 5.4% during the 4th quarter. Franklin Resources Inc. now owns 2,825,954 shares of the company's stock worth $2,318,102,000 after purchasing an additional 144,633 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in McKesson by 5.6% during the 3rd quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company's stock worth $1,850,001,000 after purchasing an additional 126,684 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company's stock.

McKesson Company Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.